Tumor Biology

, Volume 33, Issue 3, pp 877–884

Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients

  • Dianke Yu
  • Juan Shi
  • Tong Sun
  • Xiaoli Du
  • Li Liu
  • Xiaojiao Zhang
  • Chao Lu
  • Xiaohu Tang
  • Meng Li
  • Lingchen Xiao
  • Zhouwei Zhang
  • Qipeng Yuan
  • Ming Yang
Research Article

DOI: 10.1007/s13277-011-0314-y

Cite this article as:
Yu, D., Shi, J., Sun, T. et al. Tumor Biol. (2012) 33: 877. doi:10.1007/s13277-011-0314-y

Abstract

The excision repair cross-complementation group 1 (ERCC1) plays an essential role in DNA repair and has been linked to resistance to platinum-based anticancer drugs among advanced non-small cell lung cancer (NSCLC) patients. We systematically evaluate whether ERCC1 Asn118Asn and C8092A genetic variants are associated with treatment response of platinum chemotherapy. We preformed a meta-analysis using ten eligible cohort studies (including 11 datasets) with a total of 1,252 NSCLC patients to summarize the existing data on the association between the ERCC1 Asn118Asn and C8092A polymorphisms and response to platinum regiments. Odds ratio or hazard ratio with 95% confidence interval were calculated to estimate the correlation. We found that neither ERCC1 C8092A polymorphism nor Asn118Asn variant is associated with different response of platinum-based treatment among advanced NSCLC patients. Additionally, these two genetic variants are not related to treatment response in either Caucasian patients or Asian patients. Our meta-analysis indicates that the ERCC1 Asn118Asn and C8092A polymorphisms may not be good prognostic biomarkers for platinum-based chemotherapy in patients with stage III–IV NSCLC.

Keywords

Chemotherapy ERCC1 Meta-analysis Pharmacogenetics Platinum 

Supplementary material

13277_2011_314_MOESM1_ESM.pdf (30 kb)
ESM 1Treatment characteristics and genotyping methods of studies included in the meta-analysis (PDF 30 kb)

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • Dianke Yu
    • 1
  • Juan Shi
    • 2
  • Tong Sun
    • 3
  • Xiaoli Du
    • 4
  • Li Liu
    • 2
  • Xiaojiao Zhang
    • 2
  • Chao Lu
    • 2
  • Xiaohu Tang
    • 2
  • Meng Li
    • 2
  • Lingchen Xiao
    • 2
  • Zhouwei Zhang
    • 2
  • Qipeng Yuan
    • 2
    • 5
  • Ming Yang
    • 2
    • 5
  1. 1.State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, Cancer Institute and HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina
  2. 2.College of Life Science and TechnologyBeijing University of Chemical TechnologyBeijingChina
  3. 3.Department of Medical OncologyDana-Farber Cancer Institute and Harvard Medical SchoolBostonUSA
  4. 4.Laboratory of Cellular Oncology, National Cancer InstituteNational Institutes of HealthBethesdaUSA
  5. 5.College of Life Science and TechnologyBeijing University of Chemical TechnologyBeijingChina

Personalised recommendations